OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 18:47 UTC. Every row links to its source record.

TBL1XR1 TBL1X/Y related 1

ENSG00000177565 · protein coding · Open Targets profile

F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units. Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of the N-Cor corepressor complex that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of N-Cor complex, thereby allowing cofactor exchange, and transcription activation. .

In 15 of 15 cancers, the evidence for TBL1XR1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751diffuse large B-cell lymphomadiffuse large B-cell lymphomadiffuse large B-cell lymphoma: somatic 0.71lymphomalymphomalymphoma: somatic 0.62lung carcinomalung carcinomalung carcinoma: somatic 0.61primary central nervous system lymphomaprimary central nervous system lymphomaprimary central nervous system lymphoma: somatic 0.61anaplastic large cell lymphomaanaplastic large cell lymphomaanaplastic large cell lymphoma: somatic 0.61adult T-cell leukemia/lymphomaadult T-cell leukemia/lymphomaadult T-cell leukemia/lymphoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61neoplasm of mature B-cellsneoplasm of mature B-cellsneoplasm of mature B-cells: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61diffuse large B-cell lymphoma of the ce…diffuse large B-cell lymphoma of the central nervous systemdiffuse large B-cell lymphoma of the central nervous system: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61nodular malignant melanomanodular malignant melanomanodular malignant melanoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.07478400319814682 (upper bound 0.15724000334739685). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of TBL1XR1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of TBL1XR1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.